Showing 581-600 of 8875 for: Cochrane Systematic Reviews Back
- Anticoagulants (extended duration) for prevention of venous thromboembolism following total hip or knee replacement or hip fracture repair
Cochrane Systematic Reviews, 30-Mar-2016
The optimal duration of thromboprophylaxis after total hip or knee replacement, or hip fracture repair remains controversial. It is common practice to administer prophylaxis using low-molecular-weight heparin (LMWH) or unfractionated heparin (UFH) until d
- Anticoagulants (heparin, low molecular weight heparin and oral anticoagulants) for intermittent claudication
Cochrane Systematic Reviews, 7-May-2014
Anticoagulant treatment for intermittent claudication might improve functional capacity and prevent acute cardiovascular complications caused by peripheral obstructive arterial disease. This is an update of the review first published in 2001.
- Anticoagulants and antiplatelet agents for preventing central venous haemodialysis catheter malfunction in patients with end‐stage kidney disease
Cochrane Systematic Reviews, 4-Apr-2016
Catheter malfunction, including thrombosis, is associated with reduced dialysis adequacy, as well as an increased risk of catheter-related bacteraemia and mortality. The role of anticoagulants in the prevention of catheter malfunction remains uncertain.
- Anticoagulants for acute ischaemic stroke
Cochrane Systematic Reviews, 22-Oct-2021
Stroke is the third leading cause of early death worldwide. Most ischaemic strokes are caused by a blood clot blocking an artery in the brain. Patient outcomes might be improved if they are offered anticoagulants that reduce their risk of developing new b
- Anticoagulants for people hospitalised with COVID‐19
Cochrane Systematic Reviews, 4-Mar-2022
The primary manifestation of coronavirus disease 2019 (COVID-19) is respiratory insufficiency that can also be related to diffuse pulmonary microthrombosis and thromboembolic events, such as pulmonary embolism, deep vein thrombosis, or arterial thrombosis
- Anticoagulants for preventing recurrence following presumed non‐cardioembolic ischaemic stroke or transient ischaemic attack
Cochrane Systematic Reviews, 15-Apr-2009
After a first ischaemic stroke, further vascular events due to thromboembolism are common and often fatal. Anticoagulants could potentially reduce the risk of such events, but any benefits could be offset by an increased risk of fatal or disabling haemorr
- Anticoagulants for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischaemic attack
Cochrane Systematic Reviews, 6-Mar-2011
People with nonrheumatic atrial fibrillation (NRAF) who have had a transient ischaemic attack (TIA) or a minor ischaemic stroke are at high risk of recurrent stroke.
- Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter
Cochrane Systematic Reviews, 28-Oct-2008
Atrial fibrillation (AF) carries a high risk of stroke and other thromboembolic events. Appropriate use of drugs to prevent thromboembolism in patients with AF involves comparing the patient's risk of stroke to the risk of hemorrhage from medication use.
- Anticoagulants versus antiplatelet agents for acute ischaemic stroke
Cochrane Systematic Reviews, 6-Mar-2011
Antiplatelet agents produce a small, but worthwhile benefit in long-term functional outcome and survival, and have become standard treatment for acute ischaemic stroke. Anticoagulants are often used as an alternative treatment, despite evidence that they
- Anticoagulants versus antiplatelet therapy for preventing stroke in patients with nonrheumatic atrial fibrillation and a history of stroke or transient ischemic attack
Cochrane Systematic Reviews, 6-Mar-2011
People with nonrheumatic atrial fibrillation (NRAF) who have had a transient ischemic attack (TIA) or minor ischemic stroke are at risk of recurrent stroke. Both warfarin and aspirin have been shown to reduce the recurrence of vascular events.
- Anticoagulants versus non-steroidal anti-inflammatories or placebo for treatment of venous thromboembolism
Cochrane Systematic Reviews, 13-May-2008
Venous thromboembolism (VTE) is the term given to any thromboembolic event (blocking of a blood vessel by a blood clot) occurring in the venous system. The current treatment recommended for VTE is anticoagulation (reduction of the blood's ability to clot)
- Anticoagulation for cerebral venous sinus thrombosis
Cochrane Systematic Reviews, 10-Aug-2011
Treatment of cerebral venous sinus thrombosis with anticoagulants has been controversial. Anticoagulants may prevent new venous infarcts, neurologic deterioration and pulmonary embolism but may also promote haemorrhages.
- Anticoagulation for people with cancer and central venous catheters
Cochrane Systematic Reviews, 1-Jun-2018
Central venous catheter (CVC) placement increases the risk of thrombosis in people with cancer. Thrombosis often necessitates the removal of the CVC, resulting in treatment delays and thrombosis-related morbidity and mortality. This is an update of the Co
- Anticoagulation for perioperative thromboprophylaxis in people with cancer
Cochrane Systematic Reviews, 11-Jul-2018
The choice of the appropriate perioperative thromboprophylaxis for people with cancer depends on the relative benefits and harms of different anticoagulants.
- Anticoagulation for the initial treatment of venous thromboembolism in people with cancer
Cochrane Systematic Reviews, 8-Dec-2021
Compared with people without cancer, people with cancer who receive anticoagulant treatment for venous thromboembolism (VTE) are more likely to develop recurrent VTE.
- Anticoagulation for the long‐term treatment of venous thromboembolism in people with cancer
Cochrane Systematic Reviews, 19-Jun-2018
Cancer increases the risk of thromboembolic events, especially in people receiving anticoagulation treatments.
- Anticoagulation therapy versus placebo for pulmonary hypertension
Cochrane Systematic Reviews, 2-Jun-2014
Elevation of pulmonary pressure is no longer a rare disease, given its multifactorial etiology. However data on the actual incidence of this condition are still limited, and controversies regarding its management are ongoing. Use of anticoagulation in the
- Anticoagulation versus placebo for heart failure in sinus rhythm
Cochrane Systematic Reviews, 18-May-2021
People with chronic heart failure (HF) are at risk of thromboembolic events, including stroke, pulmonary embolism, and peripheral arterial embolism; coronary ischaemic events also contribute to the progression of HF. The use of long-term oral anticoagulat
- Anticonvulsant drugs for acute and chronic pain
Cochrane Systematic Reviews, 3-Sep-2009
Anticonvulsant drugs have been used in the management of pain since the 1960s. The clinical impression is that they are useful for chronic neuropathic pain, especially when the pain is lancinating or burning. Readers are referred to reviews of carbamazepi
- Anticonvulsant drugs for migraine prophylaxis
Cochrane Systematic Reviews, 27-May-2016
This review has been split and updated in a series of four new reviews, all with the author byline Linde M, Mulleners WM, Chronicle EP, McCrory DC. The new titles are:
